---
title: Safety of Percutaneous Tracheostomy in Clopidogrel and Selective Serotonin Reuptake Inhibitors
nct_id: NCT02074254
overall_status: WITHDRAWN
sponsor: Ohio State University
study_type: OBSERVATIONAL
primary_condition: Tracheostomy Complication
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02074254.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02074254"
ct_last_update_post_date: 2021-11-10
last_seen_at: "2026-05-12T07:06:51.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Safety of Percutaneous Tracheostomy in Clopidogrel and Selective Serotonin Reuptake Inhibitors

**NCT ID:** [NCT02074254](https://clinicaltrials.gov/study/NCT02074254)

## Key Facts

- **Status:** WITHDRAWN
- **Why Stopped:** Not sure. PI is no longer at OSU.
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 0
- **Lead Sponsor:** Ohio State University
- **Conditions:** Tracheostomy Complication
- **Start Date:** 2012-03-22
- **Completion Date:** 2012-05-09
- **CT.gov Last Update:** 2021-11-10

## Brief Summary

Safety of Percutaneous Tracheostomy in Clopidogrel and Selective Serotonin Reuptake Inhibitors

## Detailed Description

We propose a retrospective review of our experience with bleeding complication in the presence of antiplatelet and SSRI therapy and compare the complications with those who were not on antiplatelet agents or SSRI.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* on antiplatelet therapy or selective serotonin reuptake inhibitors(SSRI)

Exclusion Criteria:

* N/A
```

## Primary Outcomes

- **a retrospective review of our experience with bleeding complication in the presence of antiplatelet and SSRI therapy and compare the complications with those who were not on antiplatelet agents or SSRI** _(time frame: 24 months)_

## Locations (2)

- OSUMC, Columbus, Ohio, United States
- University Hospital, OSUMC 473 W 12th Ave, Columbus, Ohio, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.osumc|columbus|ohio|united states` — added _(2026-05-12)_
- `locations.university hospital, osumc 473 w 12th ave|columbus|ohio|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02074254.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02074254*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*